Univerza v Ljubljani
Medicinska fakulteta

PHARMACOGENETICS LABORATORY
Institute of Biochemistry

http://ibk.mf.uni-lj.si/people/dolzan

The aim of pharmacogenomics in medicine is to improve diagnostics, prediction of treatment response and treatment efficacy for individual patients based on their genetic variability. Understanding which genetic factors are involved in disease susceptibility enables faster diagnosis, therefore allowing faster treatment. Adjustment of treatment selection or dosage based on patients' demographic, clinical and genetic characteristics may improve treatment efficacy and reduce the occurrence of complications due to treatment.

PHARMACOGENOMICS **PERSONALISED MEDICINE**
TRANSLATIONAL RESEARCH **EDUCATION**
SCIENCE COMMUNICATION



Clinical collaborations:

Institute of Oncology Ljubljana
UMC Ljubljana
University Psychiatric Clinic Ljubljana
UMC Maribor
SB Celje

ZD Ljubljana
ZD Kočevje
ZD Sevnica
ZD Litija
ZD Trebnje

PROGRAMS AND PROJECTS

ARRS P1-0170 **Molecular mechanisms of regulation of cellular processes related to some human diseases** (Vita Dolžan)

ARRS L3-8203 **Serum, genetic and epigenetic markers of risk for developing, progress and treatment response in asbestos related diseases** (Vita Dolžan)

ARRS J3-1753 **Molecular predictors of radiation treatment response in breast cancer** (Katja Goričar)

Horizon 2020 Grant No. 668353 – Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen
1. 1. 2016 – 31. 12. 2020 (Henk-Jan Guchelaar, Leiden)

---

cost
EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY

CA15129 **DiMoPEx** 11. 4. 2016 – 10. 4. 2020 (Lygia Therese Budnik, Hamburg)
CA15132 **hCOMET** 12. 4. 2016 – 11. 4. 2020 (Andrew Collins, Oslo)